Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin

Abstract

This paper discusses the possibilities and benefits of early combination therapy and the application features of a fixed-dose combination of metformin and alogliptin (Vipdomet®) in the treatment of type 2 diabetes mellitus (DM 2).

Keywords

• alogliptin
• metformin
• dpp-4 inhibitors
• combination therapy
• vipdomet®
• fixed-dose combination therapy
• efficacy
• safety